Questions and Answers
What is the mechanism of action for Abciximab?
Which drug is primarily used for prophylaxis in patients with prosthetic heart valves?
What is a common condition associated with the absence of the gpIIb/IIIa receptor?
Which statement correctly describes the action of dipyridamole?
Signup and view all the answers
Eptifibatide works by which of the following mechanisms?
Signup and view all the answers
Tirofiban is classified as which type of drug?
Signup and view all the answers
What is a limitation of using dipyridamole as an antithrombotic agent?
Signup and view all the answers
Which drug can lead to extracellular accumulation of adenosine and prolonged action due to inhibition of uptake in red blood cells?
Signup and view all the answers
What is the primary mechanism by which blockers of platelet ADP receptors exert their effects?
Signup and view all the answers
Which of the following drugs is specifically mentioned as having a lower incidence of serious adverse effects compared to another drug?
Signup and view all the answers
What condition can result from genetic deficiencies in enzymes that metabolize clopidogrel?
Signup and view all the answers
Which glycoprotein receptor is involved in the final common pathway for platelet aggregation?
Signup and view all the answers
Which agent is specifically indicated for the treatment of hemophilia A?
Signup and view all the answers
What is the approved maintenance dose of clopidogrel for prophylaxis of thrombosis?
Signup and view all the answers
What is the primary role of Vitamin K in the body?
Signup and view all the answers
Why has ticlopidine been largely replaced by clopidogrel in clinical practice?
Signup and view all the answers
Which of the following factors requires bile salts for absorption?
Signup and view all the answers
What is the role of glycoprotein IIb/IIIa receptor antagonists?
Signup and view all the answers
Which of the following statements best describes clopidogrel's mechanism of action?
Signup and view all the answers
What is one of the local methods to control bleeding?
Signup and view all the answers
What is the main action of aminocaproic acid and tranexamic acid?
Signup and view all the answers
Which of the following agents is classified as a sclerosing agent?
Signup and view all the answers
What is the therapeutic use of Vitamin K?
Signup and view all the answers
Which vitamin is synthesized by intestinal bacteria?
Signup and view all the answers
What is a key reason for preferring recombinant preparations of plasma fractions over traditional ones?
Signup and view all the answers
Which agent is considered a more potent analogue of aminocaproic acid?
Signup and view all the answers
For which condition is aminocaproic acid primarily recommended as a treatment?
Signup and view all the answers
In what situation is tranexamic acid used as adjunctive therapy?
Signup and view all the answers
What is one indication for the prophylaxis of rebleeding with aminocaproic acid?
Signup and view all the answers
What therapeutic use does aminocaproic acid NOT serve?
Signup and view all the answers
What is the purpose of administering vitamin K to newborns?
Signup and view all the answers
Which condition is associated with a bleeding tendency that does not respond to vitamin K?
Signup and view all the answers
What can occur if factor activity is less than 5–10% of normal?
Signup and view all the answers
Which coagulation defect is associated with factor VIII deficiency?
Signup and view all the answers
What is the mode of administration for plasma protein preparations used in treating coagulation defects?
Signup and view all the answers
What adverse effects can rapid intravenous administration of parenteral vitamin K1 cause?
Signup and view all the answers
What type of vitamin K is usually administered to correct deficiencies due to dietary issues?
Signup and view all the answers
What is the typical dose of vitamin K recommended for newborns after birth?
Signup and view all the answers
Vitamin K is administered to all newborns to prevent hypoketosis.
Signup and view all the answers
Severe hepatic failure can lead to a bleeding tendency that does not respond to vitamin K due to reduced synthesis of clotting factors.
Signup and view all the answers
Plasma coagulation factors can cause spontaneous bleeding if their activity exceeds 15% of normal levels.
Signup and view all the answers
Parenteral vitamin K1 is insoluble in water and must be dissolved in oil for administration.
Signup and view all the answers
Factor IX deficiency is also known as Christmas disease.
Signup and view all the answers
The recommended dose of vitamin K for newborns is 2–3 mg after birth.
Signup and view all the answers
Rapid intravenous administration of parenteral vitamin K1 can cause chest pain and dyspnea.
Signup and view all the answers
Hemophilia A is characterized by a deficiency of factor X.
Signup and view all the answers
Plasma fractions are commonly prepared from blood pooled from multiple individuals, thus they are associated with a high risk of exposure to infections such as hepatitis and HIV.
Signup and view all the answers
Tranexamic acid is a less potent analogue of aminocaproic acid.
Signup and view all the answers
Aminocaproic acid is utilized as adjunctive therapy in conditions involving excessive fibrinolysis.
Signup and view all the answers
The primary therapeutic use of aminocaproic acid includes the prevention of bleeding from tissues that lack plasminogen activators.
Signup and view all the answers
Prophylaxis for rebleeding from an intracranial aneurysm is a therapeutic use for tranexamic acid.
Signup and view all the answers
Patients lacking the gpIIb/IIIa receptor may have Glanzmann's thrombasthenia.
Signup and view all the answers
Aminocaproic acid should never be used in cases where there is a risk of bleeding due to toxicity from antifibrinolytic drugs.
Signup and view all the answers
Abciximab is a small synthetic peptide that blocks the binding of platelets to fibrinogen.
Signup and view all the answers
Dipyridamole works by inhibiting phosphodiesterase, leading to increased cGMP levels and vasodilation.
Signup and view all the answers
Eptifibatide and tirofiban are both classified as low molecular weight peptides.
Signup and view all the answers
Tirofiban is primarily used to treat patients with hemophilia A.
Signup and view all the answers
The use of dipyridamole is limited to prophylaxis in patients with prosthetic heart valves.
Signup and view all the answers
Eptifibatide binds to the gpIIb/IIIa receptor and enhances platelet activation.
Signup and view all the answers
Dipyridamole's action results in the accumulation of adenosine in platelets and RBCs.
Signup and view all the answers
Vitamin K is essential for the synthesis of factors II, VII, IX, and Y by the liver.
Signup and view all the answers
Aminocaproic acid and tranexamic acid are inhibitors of the hemostatic system.
Signup and view all the answers
Vitamin K2 is synthesized by liver cells in the human body.
Signup and view all the answers
Fresh blood or plasma transfusions serve as sources of coagulation factors.
Signup and view all the answers
Ethamsylate is administered orally to reduce capillary bleeding.
Signup and view all the answers
Thromboplastin is a form of vitamin K necessary for blood coagulation.
Signup and view all the answers
Calcium acts as a coagulant factor and is identified as factor IV.
Signup and view all the answers
Vitamin C is critical for the absorption of vitamin K in the intestine.
Signup and view all the answers
Ticlopidine and clopidogrel both irreversibly inhibit the binding of ADP to its receptors on platelets.
Signup and view all the answers
Clopidogrel is a prodrug that relies on its inactive metabolite for therapeutic efficacy.
Signup and view all the answers
People with genetic deficiencies in the enzymes that metabolize clopidogrel are referred to as poor metabolizers.
Signup and view all the answers
Activation of glycoprotein IIb/IIIa receptors is not essential for platelet aggregation.
Signup and view all the answers
Clopidogrel and ticlopidine have the same incidence of serious adverse effects.
Signup and view all the answers
Eptifibatide is a type of drug that blocks platelet ADP receptors.
Signup and view all the answers
Clopidogrel is approved for prophylaxis of thromboembolism in both cerebrovascular and cardiovascular diseases.
Signup and view all the answers
The maintenance dose of clopidogrel is 75 mg/d orally.
Signup and view all the answers
What distinguishes clopidogrel from ticlopidine in terms of adverse effects?
Signup and view all the answers
Which drug is considered a prodrug that requires metabolic activation to exert its therapeutic effects?
Signup and view all the answers
What is the primary mechanism by which blockers of glycoprotein IIb/IIIa receptors facilitate their antithrombotic effect?
Signup and view all the answers
Explain the genetic variability associated with clopidogrel metabolism.
Signup and view all the answers
Identify a key reason why ticlopidine is not preferred in current clinical practice.
Signup and view all the answers
What common vascular diseases is clopidogrel approved to prevent through thrombosis prophylaxis?
Signup and view all the answers
How do blockers of platelet ADP receptors influence platelet activation?
Signup and view all the answers
What is the maintenance dose of clopidogrel for adults?
Signup and view all the answers
What is Glanzmann's thrombasthenia caused by?
Signup and view all the answers
What is the primary therapeutic use of dipyridamole?
Signup and view all the answers
Describe the mechanism by which Eptifibatide exerts its antithrombotic effects.
Signup and view all the answers
What limitation does dipyridamole have in its use as an antithrombotic agent?
Signup and view all the answers
How does dipyridamole influence adenosine levels in the body?
Signup and view all the answers
Which patients are indicated for the use of abciximab during coronary intervention?
Signup and view all the answers
How does Tirofiban function in inhibiting platelet aggregation?
Signup and view all the answers
What is the effect of phosphodiesterase (PDE) inhibition by dipyridamole on vascular dynamics?
Signup and view all the answers
What role does Vitamin K play in liver function related to clotting factors?
Signup and view all the answers
How do aminocaproic acid and tranexamic acid function in hemostatic therapy?
Signup and view all the answers
What are the indications for administering Vitamin K to newborns?
Signup and view all the answers
What is the significance of bile salts in the absorption of Vitamin K?
Signup and view all the answers
Describe a local method used to control bleeding.
Signup and view all the answers
What are sclerosing agents and their purpose in hemostatic treatment?
Signup and view all the answers
How is antihemophilic globulin used in the context of hemophilia A?
Signup and view all the answers
Explain the role of physical agents in local hemostatic methods.
Signup and view all the answers
What is the importance of administering vitamin K to newborns, particularly premature infants?
Signup and view all the answers
What serious adverse effects can result from rapid intravenous administration of parenteral vitamin K1?
Signup and view all the answers
What bleeding tendency is associated with severe hepatic failure?
Signup and view all the answers
At what factor activity level does spontaneous bleeding typically occur?
Signup and view all the answers
Identify the conditions associated with factor VIII and factor IX deficiencies.
Signup and view all the answers
What is the typical method of administering plasma protein preparations used to treat coagulation defects?
Signup and view all the answers
What dietary-related issues can vitamin K supplementation correct?
Signup and view all the answers
Why is it crucial to monitor factor activity levels in patients with hemophilia?
Signup and view all the answers
What is a significant risk associated with preparing plasma fractions from pooled blood?
Signup and view all the answers
How do aminocaproic acid and tranexamic acid function as inhibitors of fibrinolysis?
Signup and view all the answers
Which therapeutic use is associated with tranexamic acid in clinical settings?
Signup and view all the answers
In what situations is aminocaproic acid utilized to prevent bleeding?
Signup and view all the answers
What is one major clinical application for both aminocaproic acid and tranexamic acid?
Signup and view all the answers
How does the potency of tranexamic acid compare to that of aminocaproic acid?
Signup and view all the answers
Clopidogrel irreversibly inhibits the binding of ADP to its receptors on ______.
Signup and view all the answers
Ticlopidine has been largely replaced by ______ because of serious adverse effects.
Signup and view all the answers
The maintenance dose of clopidogrel is ______ mg/d orally.
Signup and view all the answers
Clopidogrel is a ______, and its therapeutic efficacy relies entirely on its active metabolite.
Signup and view all the answers
Blockers of platelet ADP receptors include Ticlopidine, Clopidogrel, and ______.
Signup and view all the answers
Activation of the glycoprotein IIb/IIIa receptor complex is the 'final common ______' for platelet aggregation.
Signup and view all the answers
Individuals with genetic deficiency in the enzymes that metabolize clopidogrel are called ______.
Signup and view all the answers
Eptifibatide and Tirofiban are types of blockers of platelet glycoprotein ______ receptors.
Signup and view all the answers
Glanzmann's thrombasthenia is a bleeding disorder associated with the absence of the ______ receptor.
Signup and view all the answers
Abciximab is a monoclonal antibody that binds to and blocks the binding of platelets to ______.
Signup and view all the answers
Eptifibatide acts by competitively blocking the ______ receptor.
Signup and view all the answers
Dipyridamole primarily inhibits phosphodiesterase leading to an increase in ______.
Signup and view all the answers
The action of dipyridamole involves the inhibition of ______ uptake, leading to its prolonged action.
Signup and view all the answers
The use of dipyridamole as an antithrombotic agent is limited to prophylaxis with ______ in specific patients.
Signup and view all the answers
Tirofiban is a peptide that binds to the ______ receptor.
Signup and view all the answers
Agents like abciximab, eptifibatide, and tirofiban have been approved for use in ______ coronary intervention.
Signup and view all the answers
To correct vitamin deficiency, especially in patients receiving oral ______.
Signup and view all the answers
Newborns should receive 1-2 mg of vitamin K directly after ______.
Signup and view all the answers
Severe hepatic failure is associated with a bleeding tendency due to reduced synthesis of ______ factors.
Signup and view all the answers
Factor VIII deficiency is known as classic ______.
Signup and view all the answers
Plasma protein preparations are administered via ______.
Signup and view all the answers
Rapid intravenous administration of parenteral vitamin K1 can cause dyspnea and ______.
Signup and view all the answers
Factor IX deficiency is also known as ______ disease.
Signup and view all the answers
Vitamin K is administered to newborns to prevent ______.
Signup and view all the answers
Vitamin K is essential for synthesis of factors II, VII, IX, and X by the ______.
Signup and view all the answers
Both vitamins K1 and K2 require ______ for absorption from the intestine.
Signup and view all the answers
Fresh blood or plasma transfusion serves as sources of ______ factors.
Signup and view all the answers
Antihemophilic globulin is also known as factor ______.
Signup and view all the answers
Vitamin K1 is a naturally occurring fat-soluble vitamin present in ______ vegetables.
Signup and view all the answers
Aminocaproic acid and tranexamic acid are inhibitors of the ______ system.
Signup and view all the answers
Sclerosing agents cause thrombosis in veins and permanent ______.
Signup and view all the answers
Vitamin K is administered to all newborns to prevent ______.
Signup and view all the answers
Aminocaproic acid is a synthetic agent that competitively inhibits ______ activation.
Signup and view all the answers
Tranexamic acid is a more potent analogue of ______ acid.
Signup and view all the answers
Therapeutic uses of aminocaproic acid include preventing bleeding from tissues rich in ______ activators.
Signup and view all the answers
Prophylaxis for rebleeding from ______ aneurysm is one of the therapeutic uses of aminocaproic acid.
Signup and view all the answers
Recombinant preparations are recommended when possible due to the risk of exposure to ______ from pooled plasma.
Signup and view all the answers
Tranexamic acid can be utilized as adjunctive therapy in cases of ______.
Signup and view all the answers
Match the following drugs used in bleeding disorders with their corresponding actions or indications:
Signup and view all the answers
Match the following vitamin types with their sources and roles:
Signup and view all the answers
Match the following local agents used to control bleeding with their descriptions:
Signup and view all the answers
Match the following systemic agents with their main characteristics:
Signup and view all the answers
Match the following reactions or conditions with the correct therapeutic use:
Signup and view all the answers
Match the symptoms or conditions with the appropriate underlying causes:
Signup and view all the answers
Match the following coagulation components with their functions:
Signup and view all the answers
Match the following methods or treatments with their corresponding conditions they address:
Signup and view all the answers
Match the following antiplatelet drugs with their characteristics:
Signup and view all the answers
Match the following glycoprotein IIb/IIIa receptor blockers with their indications:
Signup and view all the answers
Match the following characteristics with their respective ADP receptor blockers:
Signup and view all the answers
Match the following complications with the corresponding antiplatelet drug:
Signup and view all the answers
Match the following indications with their respective treatments:
Signup and view all the answers
Match the following characteristics with their respective platelet aggregation pathways:
Signup and view all the answers
Match the following drugs with their mechanism of action:
Signup and view all the answers
Match the following drugs with their metabolization status:
Signup and view all the answers
Match the following platelet inhibitors with their specific actions:
Signup and view all the answers
Match the following platelet inhibitors with their usage:
Signup and view all the answers
Match the following drugs with their origin or type:
Signup and view all the answers
Match the following drugs with their effect on adenosine:
Signup and view all the answers
Match the following drugs with their specific therapeutic limitation:
Signup and view all the answers
Match the following conditions with the associated receptor deficiency:
Signup and view all the answers
Match the following drugs with their mechanism of platelet activity modulation:
Signup and view all the answers
Match the following types of actions to the corresponding drugs:
Signup and view all the answers
Match the vitamin K usage with its corresponding purpose:
Signup and view all the answers
Match the coagulation factor deficiencies with their corresponding conditions:
Signup and view all the answers
Match the adverse effects with their corresponding causes related to vitamin K1:
Signup and view all the answers
Match the dosing recommendations for vitamin K with the target groups:
Signup and view all the answers
Match the implications of vitamin K deficiency with their related effects:
Signup and view all the answers
Match the treatment methods for coagulation disorders with their attributes:
Signup and view all the answers
Match the following therapeutic uses with the correct drug:
Signup and view all the answers
Match the conditions to the factors they are associated with:
Signup and view all the answers
Match the following drugs with their potency:
Signup and view all the answers
Match the reason for administering vitamin K with the related scenarios:
Signup and view all the answers
Match the following conditions with their related drug usage:
Signup and view all the answers
Match the following drugs with their action against bleeding:
Signup and view all the answers
Match the following drugs with their recommendation based on exposure risk:
Signup and view all the answers
Match the following descriptions with the correct drug:
Signup and view all the answers
Study Notes
Blockers of Platelet ADP Receptors
- Agents: Ticlopidine, Clopidogrel, Prasugrel
- These drugs irreversibly inhibit ADP binding to platelet receptors, preventing glycoprotein IIb/IIIa activation necessary for platelet aggregation with fibrinogen.
- Clopidogrel is approved for thrombus prophylaxis in cerebrovascular and cardiovascular diseases, particularly for coronary artery disease and peripheral vascular disease, with a maintenance dose of 75 mg/day orally.
- Clopidogrel is a prodrug; its efficacy depends on conversion to an active metabolite. Genetic variations may lead some individuals to be “poor metabolizers,” limiting the drug's effectiveness.
- Ticlopidine has largely been replaced by clopidogrel due to serious side effects like neutropenia and increased bleeding risks, which are less frequent with clopidogrel.
Blockers of Platelet Glycoprotein IIb/IIIa Receptors
- Agents: Abciximab, Eptifibatide, Tirofiban
- Activation of glycoprotein IIb/IIIa receptors signals the final pathway for platelet aggregation and fibrinogen binding. Individuals lacking this receptor suffer from Glanzmann's thrombasthenia, a bleeding disorder.
- Abciximab (a monoclonal antibody fragment) directly blocks glycoprotein IIb/IIIa, inhibiting platelet-fibrinogen binding.
- Eptifibatide is a small synthetic peptide that competitively inhibits the IIb/IIIa receptor.
- Tirofiban is a low molecular weight peptide that attaches to the glycoprotein IIIb/IIIa receptor.
- These agents are indicated for patients undergoing percutaneous coronary interventions, unstable angina, and post-myocardial infarction conditions.
Dipyridamole
- Inhibits phosphodiesterase (PDE) to increase cGMP levels, promoting vasodilation and reducing platelet activity.
- Also inhibits adenosine uptake in platelets and red blood cells, leading to extracellular accumulation and extended effects.
- Primarily used for prophylaxis in patients with prosthetic heart valves, often combined with warfarin.
Systemic Agents for Bleeding Disorders
- Vitamin K: Necessary for synthesis of coagulation factors II, VII, IX, and X. Available in oral and injectable forms.
- Vitamin C and Rutin: Maintain vascular wall integrity.
- Fresh blood/plasma transfusions: Provide necessary coagulation factors.
- Plasma Fractions: Includes thromboplastin (factor III), antihemophilic globulin (factor VIII), and calcium.
- Aminocaproic and Tranexamic acid: Inhibit the fibrinolytic system.
- Ethamsylate (Dicynone): Reduces capillary bleeding when given intramuscularly.
Vitamin K
- Sources: Vitamin K1 (phytomenadione) found in green vegetables; Vitamin K2 synthesized by intestinal bacteria.
- Bile salts are required for absorption of both K1 and K2.
- Medicinal uses include reversing bleeding from warfarin overdose, addressing dietary deficiencies, and preventing neonatal hypothrombinemia.
- Adverse effects can occur with rapid intravenous administration of vitamin K1.
Plasma Fractions
- Coagulation factor deficiencies can lead to spontaneous bleeding when factor activity drops below 5-10% of normal.
- Hemophilia A (factor VIII deficiency) and Hemophilia B (factor IX deficiency) are common hereditary bleeding disorders.
- Plasma preparations for treatment are often derived from multiple donors, risking infection exposure. Recombinant products are preferred when available.
Inhibitors of Fibrinolysis
- Aminocaproic Acid: Competes with plasminogen, reducing activation.
- Tranexamic Acid: More potent analog of aminocaproic acid with similar action.
- Therapeutic uses include preventing bleeding in surgeries involving rich tissues in plasminogen activators and treating hemorrhages due to fibrinolytic drug toxicity.
Blockers of Platelet ADP Receptors
- Agents: Ticlopidine, Clopidogrel, Prasugrel
- These drugs irreversibly inhibit ADP binding to platelet receptors, preventing glycoprotein IIb/IIIa activation necessary for platelet aggregation with fibrinogen.
- Clopidogrel is approved for thrombus prophylaxis in cerebrovascular and cardiovascular diseases, particularly for coronary artery disease and peripheral vascular disease, with a maintenance dose of 75 mg/day orally.
- Clopidogrel is a prodrug; its efficacy depends on conversion to an active metabolite. Genetic variations may lead some individuals to be “poor metabolizers,” limiting the drug's effectiveness.
- Ticlopidine has largely been replaced by clopidogrel due to serious side effects like neutropenia and increased bleeding risks, which are less frequent with clopidogrel.
Blockers of Platelet Glycoprotein IIb/IIIa Receptors
- Agents: Abciximab, Eptifibatide, Tirofiban
- Activation of glycoprotein IIb/IIIa receptors signals the final pathway for platelet aggregation and fibrinogen binding. Individuals lacking this receptor suffer from Glanzmann's thrombasthenia, a bleeding disorder.
- Abciximab (a monoclonal antibody fragment) directly blocks glycoprotein IIb/IIIa, inhibiting platelet-fibrinogen binding.
- Eptifibatide is a small synthetic peptide that competitively inhibits the IIb/IIIa receptor.
- Tirofiban is a low molecular weight peptide that attaches to the glycoprotein IIIb/IIIa receptor.
- These agents are indicated for patients undergoing percutaneous coronary interventions, unstable angina, and post-myocardial infarction conditions.
Dipyridamole
- Inhibits phosphodiesterase (PDE) to increase cGMP levels, promoting vasodilation and reducing platelet activity.
- Also inhibits adenosine uptake in platelets and red blood cells, leading to extracellular accumulation and extended effects.
- Primarily used for prophylaxis in patients with prosthetic heart valves, often combined with warfarin.
Systemic Agents for Bleeding Disorders
- Vitamin K: Necessary for synthesis of coagulation factors II, VII, IX, and X. Available in oral and injectable forms.
- Vitamin C and Rutin: Maintain vascular wall integrity.
- Fresh blood/plasma transfusions: Provide necessary coagulation factors.
- Plasma Fractions: Includes thromboplastin (factor III), antihemophilic globulin (factor VIII), and calcium.
- Aminocaproic and Tranexamic acid: Inhibit the fibrinolytic system.
- Ethamsylate (Dicynone): Reduces capillary bleeding when given intramuscularly.
Vitamin K
- Sources: Vitamin K1 (phytomenadione) found in green vegetables; Vitamin K2 synthesized by intestinal bacteria.
- Bile salts are required for absorption of both K1 and K2.
- Medicinal uses include reversing bleeding from warfarin overdose, addressing dietary deficiencies, and preventing neonatal hypothrombinemia.
- Adverse effects can occur with rapid intravenous administration of vitamin K1.
Plasma Fractions
- Coagulation factor deficiencies can lead to spontaneous bleeding when factor activity drops below 5-10% of normal.
- Hemophilia A (factor VIII deficiency) and Hemophilia B (factor IX deficiency) are common hereditary bleeding disorders.
- Plasma preparations for treatment are often derived from multiple donors, risking infection exposure. Recombinant products are preferred when available.
Inhibitors of Fibrinolysis
- Aminocaproic Acid: Competes with plasminogen, reducing activation.
- Tranexamic Acid: More potent analog of aminocaproic acid with similar action.
- Therapeutic uses include preventing bleeding in surgeries involving rich tissues in plasminogen activators and treating hemorrhages due to fibrinolytic drug toxicity.
Blockers of Platelet ADP Receptors
- Agents: Ticlopidine, Clopidogrel, Prasugrel
- These drugs irreversibly inhibit ADP binding to platelet receptors, preventing glycoprotein IIb/IIIa activation necessary for platelet aggregation with fibrinogen.
- Clopidogrel is approved for thrombus prophylaxis in cerebrovascular and cardiovascular diseases, particularly for coronary artery disease and peripheral vascular disease, with a maintenance dose of 75 mg/day orally.
- Clopidogrel is a prodrug; its efficacy depends on conversion to an active metabolite. Genetic variations may lead some individuals to be “poor metabolizers,” limiting the drug's effectiveness.
- Ticlopidine has largely been replaced by clopidogrel due to serious side effects like neutropenia and increased bleeding risks, which are less frequent with clopidogrel.
Blockers of Platelet Glycoprotein IIb/IIIa Receptors
- Agents: Abciximab, Eptifibatide, Tirofiban
- Activation of glycoprotein IIb/IIIa receptors signals the final pathway for platelet aggregation and fibrinogen binding. Individuals lacking this receptor suffer from Glanzmann's thrombasthenia, a bleeding disorder.
- Abciximab (a monoclonal antibody fragment) directly blocks glycoprotein IIb/IIIa, inhibiting platelet-fibrinogen binding.
- Eptifibatide is a small synthetic peptide that competitively inhibits the IIb/IIIa receptor.
- Tirofiban is a low molecular weight peptide that attaches to the glycoprotein IIIb/IIIa receptor.
- These agents are indicated for patients undergoing percutaneous coronary interventions, unstable angina, and post-myocardial infarction conditions.
Dipyridamole
- Inhibits phosphodiesterase (PDE) to increase cGMP levels, promoting vasodilation and reducing platelet activity.
- Also inhibits adenosine uptake in platelets and red blood cells, leading to extracellular accumulation and extended effects.
- Primarily used for prophylaxis in patients with prosthetic heart valves, often combined with warfarin.
Systemic Agents for Bleeding Disorders
- Vitamin K: Necessary for synthesis of coagulation factors II, VII, IX, and X. Available in oral and injectable forms.
- Vitamin C and Rutin: Maintain vascular wall integrity.
- Fresh blood/plasma transfusions: Provide necessary coagulation factors.
- Plasma Fractions: Includes thromboplastin (factor III), antihemophilic globulin (factor VIII), and calcium.
- Aminocaproic and Tranexamic acid: Inhibit the fibrinolytic system.
- Ethamsylate (Dicynone): Reduces capillary bleeding when given intramuscularly.
Vitamin K
- Sources: Vitamin K1 (phytomenadione) found in green vegetables; Vitamin K2 synthesized by intestinal bacteria.
- Bile salts are required for absorption of both K1 and K2.
- Medicinal uses include reversing bleeding from warfarin overdose, addressing dietary deficiencies, and preventing neonatal hypothrombinemia.
- Adverse effects can occur with rapid intravenous administration of vitamin K1.
Plasma Fractions
- Coagulation factor deficiencies can lead to spontaneous bleeding when factor activity drops below 5-10% of normal.
- Hemophilia A (factor VIII deficiency) and Hemophilia B (factor IX deficiency) are common hereditary bleeding disorders.
- Plasma preparations for treatment are often derived from multiple donors, risking infection exposure. Recombinant products are preferred when available.
Inhibitors of Fibrinolysis
- Aminocaproic Acid: Competes with plasminogen, reducing activation.
- Tranexamic Acid: More potent analog of aminocaproic acid with similar action.
- Therapeutic uses include preventing bleeding in surgeries involving rich tissues in plasminogen activators and treating hemorrhages due to fibrinolytic drug toxicity.
Blockers of Platelet ADP Receptors
- Agents: Ticlopidine, Clopidogrel, Prasugrel
- These drugs irreversibly inhibit ADP binding to platelet receptors, preventing glycoprotein IIb/IIIa activation necessary for platelet aggregation with fibrinogen.
- Clopidogrel is approved for thrombus prophylaxis in cerebrovascular and cardiovascular diseases, particularly for coronary artery disease and peripheral vascular disease, with a maintenance dose of 75 mg/day orally.
- Clopidogrel is a prodrug; its efficacy depends on conversion to an active metabolite. Genetic variations may lead some individuals to be “poor metabolizers,” limiting the drug's effectiveness.
- Ticlopidine has largely been replaced by clopidogrel due to serious side effects like neutropenia and increased bleeding risks, which are less frequent with clopidogrel.
Blockers of Platelet Glycoprotein IIb/IIIa Receptors
- Agents: Abciximab, Eptifibatide, Tirofiban
- Activation of glycoprotein IIb/IIIa receptors signals the final pathway for platelet aggregation and fibrinogen binding. Individuals lacking this receptor suffer from Glanzmann's thrombasthenia, a bleeding disorder.
- Abciximab (a monoclonal antibody fragment) directly blocks glycoprotein IIb/IIIa, inhibiting platelet-fibrinogen binding.
- Eptifibatide is a small synthetic peptide that competitively inhibits the IIb/IIIa receptor.
- Tirofiban is a low molecular weight peptide that attaches to the glycoprotein IIIb/IIIa receptor.
- These agents are indicated for patients undergoing percutaneous coronary interventions, unstable angina, and post-myocardial infarction conditions.
Dipyridamole
- Inhibits phosphodiesterase (PDE) to increase cGMP levels, promoting vasodilation and reducing platelet activity.
- Also inhibits adenosine uptake in platelets and red blood cells, leading to extracellular accumulation and extended effects.
- Primarily used for prophylaxis in patients with prosthetic heart valves, often combined with warfarin.
Systemic Agents for Bleeding Disorders
- Vitamin K: Necessary for synthesis of coagulation factors II, VII, IX, and X. Available in oral and injectable forms.
- Vitamin C and Rutin: Maintain vascular wall integrity.
- Fresh blood/plasma transfusions: Provide necessary coagulation factors.
- Plasma Fractions: Includes thromboplastin (factor III), antihemophilic globulin (factor VIII), and calcium.
- Aminocaproic and Tranexamic acid: Inhibit the fibrinolytic system.
- Ethamsylate (Dicynone): Reduces capillary bleeding when given intramuscularly.
Vitamin K
- Sources: Vitamin K1 (phytomenadione) found in green vegetables; Vitamin K2 synthesized by intestinal bacteria.
- Bile salts are required for absorption of both K1 and K2.
- Medicinal uses include reversing bleeding from warfarin overdose, addressing dietary deficiencies, and preventing neonatal hypothrombinemia.
- Adverse effects can occur with rapid intravenous administration of vitamin K1.
Plasma Fractions
- Coagulation factor deficiencies can lead to spontaneous bleeding when factor activity drops below 5-10% of normal.
- Hemophilia A (factor VIII deficiency) and Hemophilia B (factor IX deficiency) are common hereditary bleeding disorders.
- Plasma preparations for treatment are often derived from multiple donors, risking infection exposure. Recombinant products are preferred when available.
Inhibitors of Fibrinolysis
- Aminocaproic Acid: Competes with plasminogen, reducing activation.
- Tranexamic Acid: More potent analog of aminocaproic acid with similar action.
- Therapeutic uses include preventing bleeding in surgeries involving rich tissues in plasminogen activators and treating hemorrhages due to fibrinolytic drug toxicity.
Blockers of Platelet ADP Receptors
- Agents: Ticlopidine, Clopidogrel, Prasugrel
- These drugs irreversibly inhibit ADP binding to platelet receptors, preventing glycoprotein IIb/IIIa activation necessary for platelet aggregation with fibrinogen.
- Clopidogrel is approved for thrombus prophylaxis in cerebrovascular and cardiovascular diseases, particularly for coronary artery disease and peripheral vascular disease, with a maintenance dose of 75 mg/day orally.
- Clopidogrel is a prodrug; its efficacy depends on conversion to an active metabolite. Genetic variations may lead some individuals to be “poor metabolizers,” limiting the drug's effectiveness.
- Ticlopidine has largely been replaced by clopidogrel due to serious side effects like neutropenia and increased bleeding risks, which are less frequent with clopidogrel.
Blockers of Platelet Glycoprotein IIb/IIIa Receptors
- Agents: Abciximab, Eptifibatide, Tirofiban
- Activation of glycoprotein IIb/IIIa receptors signals the final pathway for platelet aggregation and fibrinogen binding. Individuals lacking this receptor suffer from Glanzmann's thrombasthenia, a bleeding disorder.
- Abciximab (a monoclonal antibody fragment) directly blocks glycoprotein IIb/IIIa, inhibiting platelet-fibrinogen binding.
- Eptifibatide is a small synthetic peptide that competitively inhibits the IIb/IIIa receptor.
- Tirofiban is a low molecular weight peptide that attaches to the glycoprotein IIIb/IIIa receptor.
- These agents are indicated for patients undergoing percutaneous coronary interventions, unstable angina, and post-myocardial infarction conditions.
Dipyridamole
- Inhibits phosphodiesterase (PDE) to increase cGMP levels, promoting vasodilation and reducing platelet activity.
- Also inhibits adenosine uptake in platelets and red blood cells, leading to extracellular accumulation and extended effects.
- Primarily used for prophylaxis in patients with prosthetic heart valves, often combined with warfarin.
Systemic Agents for Bleeding Disorders
- Vitamin K: Necessary for synthesis of coagulation factors II, VII, IX, and X. Available in oral and injectable forms.
- Vitamin C and Rutin: Maintain vascular wall integrity.
- Fresh blood/plasma transfusions: Provide necessary coagulation factors.
- Plasma Fractions: Includes thromboplastin (factor III), antihemophilic globulin (factor VIII), and calcium.
- Aminocaproic and Tranexamic acid: Inhibit the fibrinolytic system.
- Ethamsylate (Dicynone): Reduces capillary bleeding when given intramuscularly.
Vitamin K
- Sources: Vitamin K1 (phytomenadione) found in green vegetables; Vitamin K2 synthesized by intestinal bacteria.
- Bile salts are required for absorption of both K1 and K2.
- Medicinal uses include reversing bleeding from warfarin overdose, addressing dietary deficiencies, and preventing neonatal hypothrombinemia.
- Adverse effects can occur with rapid intravenous administration of vitamin K1.
Plasma Fractions
- Coagulation factor deficiencies can lead to spontaneous bleeding when factor activity drops below 5-10% of normal.
- Hemophilia A (factor VIII deficiency) and Hemophilia B (factor IX deficiency) are common hereditary bleeding disorders.
- Plasma preparations for treatment are often derived from multiple donors, risking infection exposure. Recombinant products are preferred when available.
Inhibitors of Fibrinolysis
- Aminocaproic Acid: Competes with plasminogen, reducing activation.
- Tranexamic Acid: More potent analog of aminocaproic acid with similar action.
- Therapeutic uses include preventing bleeding in surgeries involving rich tissues in plasminogen activators and treating hemorrhages due to fibrinolytic drug toxicity.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
Test your knowledge on ADP receptor blockers like Ticlopidine, Clopidogrel, and Prasugrel. This quiz covers their action, mechanism of inhibition, and clinical implications. Perfect for students in pharmacology or medical courses!